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PEMENCILAN DAN PENURUNAN SELEKTIF MITRAGININA, SINTESIS DAN 
PENCIRIAN TERBITAN INDOL BARU DAN KAJIAN KEAKTIFAN BIOLOGI 
TERPILIH MEREKA  
ABSTRAK 
Mitraginina (MGT) memiliki sifat analgesik yang poten tetapi ketoksikan MGT telah 
juga dilaporkan. Objektif utama tesis ini adalah untuk memencilkan MGT bagi 
pengubahsuaian lanjutan struktur dan juga untuk mensintesis terbitan indolnya bagi menilai 
aktiviti antiproliferatif, antioksida dan antinosiseptif masing-masing. MGT telah dipencilkan 
daripada daun M. speciosa dengan menggunakan prosedur penulenan yang ringkas dan 
berkesan. Pelbagai silana telah digunakan untuk menurunkan kumpulan karbonil dan ikatan 
dubel indol bagi MGT tetapi hanya ikatan berkembar indol telah berjaya diturunkan kepada 
indolina [CDR80 ((E)-metil 2-((2S,3S,12bS)-3-etil-8-metoksi-1,2,3,4,6,7,7a,12,12a,12b-
dekahidroindolo[2,3-a]quinolizin-2-il)-3-metoksiakrilat)]. Tindak balas Pictet-Spengler telah 
diubahsuai dengan menggunakan 5-metoksitriptamina dan asid trifluoroasetik dalam medium 
akueus untuk mensintesis terbitan indol yang baru yang telah dicirikan dan dikenalpastikan 
sebagai CDR81 (6- metoksi-1-fenil-2,3,4,9-tetrahidro-1H-pyrido[3,4-b]indol) , CDR83 (6-
metoksi-1-metil-2,3,4,9-tetrahidro-1H-pirido[3,4-b]indol), CDR82 (6-metoksi-1-(4-
metoksifenil)-2,3,4,9-tetrahidro-1H-pirido[3,4-b]indol) dan CDR84 (2-metoksi-4-(6-metoksi-
2,3,4,9-tetrahidro-1H-pirido[3,4-b]indol-1-l) fenol). Konfigurasi mutlak C-1 telah 
dikenalpastikan sebagai S dengan menggunakan analisis NMR, analisis CD (circular 
dichroism) spektra dan analisis data kristal tunggal dengan merujuk kepada peraturan 
keutamaan Cahn-Ingold. Empat terbitan indol baru iaitu CDR81, CDR82, CDR83  dan 
CDR84  telah dinilai  menggunakan pelbagai panel sel kanser manusia: HT 29, K 562,HCT 
116, MCF -7, CEM SS, HEPG2, SH - 5YSY, MDA -MB- 231 dan Hela. Sebagai tambahan, 
CDR80  dan MTG juga telah diuji terhadap barisan sel kanser K 562 dan HCT 116. CDR82 
telah didapati paling aktif  terhadap barisan sel kanser  K 562 , HCT 116 dan HT29  dengan  
xxxiii 
 selektiviti yang baik berbanding dengan barisan sel kawalan iaitu NIH/3T3 , CCD18 -Co dan 
B98 -5. Di samping itu, CDR82 menunjukkan aktiviti dan selekviti yang lebih baik daripada 
ubat-ubatan antikanser piawai iaitu cisplatin , asid betulinik dan 5 -fluorourasil bagi barisan 
sel kanser HT29 (SI = 3.89 ), K 526 (SI = 8.71 ) dan HCT116 (SI = 5.68 ) masing-masing. 
CDR81 merupakan terbitan yang kedua paling aktif, CDR83 menunjukkan aktiviti yang 
lemah dan CDR84 tiada mempunyai aktiviti antiproliferatif. Terbitan indol ini telah didapati 
mempamerkan ciri antioksida yang sederhana berdasarkan gabungan cerakin DPPH, ABTS 
dan kuasa penurunan. CDR84 mempamerkan  aktiviti antioksida yang paling aktif 
disebabkan kehadiran kedua-dua kumpulan indol dan fenolik pada strukturnya sedangkan 
terbitan β-karbolina yang lain tidak mempunyai kumpulan fenolik tersebut. Akan tetapi tiada 
satu pun daripada keempat-empat terbitan ini  menunjukkan aktiviti analgesik pusat seperti 
yang dipamerkan oleh mitraginina.                                                          
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ISOLATION AND SELECTIVE REDUCTION OF MITRAGYNINE, SYNTHESIS 
AND CHARACTERIZATION OF NEW INDOLE DERIVATIVES AND THEIR 
SELECTED BIOLOGICAL ACTIVITY STUDIES  
ABSTRACT 
           Mitragynine (MTG) possesses potent analgesic properties but the toxic effects of MTG 
have also been reported. The main objective of this thesis is to isolate MTG for further 
structural modification and also to synthesize its indole derivatives and evaluate their 
antiproliferative, antioxidant and antinociceptive activities. MTG was isolated from M. 
speciosa leaves using a simple and effective purification procedure. Various silanes were 
used to reduce the carbonyl and indole double bonds of MTG but only the indole double bond 
was successfully reduced to indoline [CDR80 ((E)-methyl 2-((2S,3S,12bS)-3-ethyl-8-
methoxy-1,2,3,4,6,7,7a,12,12a,12b-decahydroindolo[2,3-a]quinolizin-2-yl)-3-methoxy acryl 
ate)]. The Pictet-Spengler reaction was modified using 5-methoxytryptamine and 
trifluoroacetic acid in an aqueous medium to synthesize new indole derivatives which were 
identified and characterized as CDR81 (6- methoxy-1-phenyl-2,3,4,9-tetrahydro-1H-
pyrido[3,4-b]indole), CDR82 (6-methoxy-1-(4-methoxyphenyl)-2,3,4,9-tetrahydro-1H-
pyrido[3,4-b]indole), CDR83 (6-methoxy-1-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-
b]indole)  and CDR84 (2-methoxy-4-(6-methoxy-2,3,4,9-tetrahydro-1H-pyrido[3,4- b]indol-
1-l)phenol). The absolute configuration of C-1 was determined as S  using NMR analysis, CD 
(circular dichroism) spectra analysis and single crystal data analysis with reference to Cahn-
Ingold priority rule. Four new indole derivatives, namely CDR81, CDR82, CDR83 and 
CDR84 were evaluated on a panel of human cancer cell line namely HT 29, K 562, HCT 116, 
MCF-7, CEM SS, HEPG2, SH-5YSY, MDA-MB-231 and HELA. In addition, CDR80 and 
MTG were tested against K 562 and HCT 116 cell lines. CDR82 was found to be the most 
active derivative, with good selectivity on the K 562, HCT 116 and HT29 cancer cell lines as 
xxxv 
 compared to the non-tumorous cell lines of NIH/3T3, CCD18-Co and B98-5. In addition, 
CDR82 showed better activity and selectivity than the standard anticancer drugs cisplatin, 
betulinic acid and 5-fluorouracil on the HT29 (SI=3.89), K 526 (SI=8.71) and HCT116 
(SI=5.68) cancer cell lines respectively. CDR81 was the second most active, CDR83 showed 
only mild activity while CDR84 has no activity. The indole derivatives were found to exhibit 
moderate anti-oxidative properties, based on a combination of DPPH, ABTS and reducing 
power assays. CDR84 showed the highest antioxidant activity due to both indole and 
phenolic groups in its structure whilst other β-carboline derivatives do not have the phenolic 
group. However, none of these derivatives showed the central analgesic activity exhibited by 
mitragynine. 
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CHAPTER 1 
INTRODUCTION 
 
1.1 Chemistry of  mitragynine (MTG) 
     Mitragyna speciosa Korth (ketum) is widely recognised in Southeast Asia as a 
unique medicinal plant because of its opioid-like effects. As the principal indole alkaloid 
from M. speciosa, mitragynine (Figure 1.1) is effective in the treatment of diarrhoea, 
intestinal infections, muscle pain and to reduce coughing (Suwanlert, 1975; Jansen and 
Prast, 1988a; Watanabe et al., 1997; Vicknasingam et al., 2010) although it is an illegal 
and controlled substance (Adkins et al., 2011). It has also been used as a tonic to 
improve work performance and as an alternative to opium (Burkill and Haniff, 1930; 
Burkill, 1935; Suwanlert, 1975; Apryani et al., 2010). Mitragynine (MTG) is the main 
alkaloid derived from M. speciosa. It has a molecular formula of C23H30N2O4 and a 
molecular weight of 398.50. Mitragynine has a melting point range of 102-106 ºC and 
boiling point of 230-240 ºC (Jansen and Prast, 1998). It is soluble in chloroform, alcohol 
and acetic acid. It has UV absorbance with lambda maximum of 254nm due to 
conjugated indole rings (Jansen and Prast, 1988) and is stable in plasma upon storage for 
at least 2 days at room temperature and up to 1 month when stored at −20 °C 
(Parthasarathy et al., 2010).  
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Figure 1.1 Structure of mitragynine (MTG). 
 
1.2 Toxicological and pharmacological effects of MTG 
     Macko et al. (1972) found no evidence of toxicity when the evaluation measured 
as tremors or convulsions in dogs at doses as high as 920 mg/kg.  Sabetghadam et al. 
(2013a) demonstrated that MTG is relatively safe at lower sub-chronic doses (1–
10mg/kg) but exhibited toxicity at the highest dose of 100mg/kg (sub-chronic: 28 days) 
in rats. The lethal effects of 200 mg/kg total alkaloid extract of M. speciosa and oral 
dose of 200 mg MTG were reported recently in rats (Janchawee et al., 2007; Azizi et al., 
2010). The acute oral LD50 toxicity levels in mice for methanolic and alkaloid extracts 
of M. speciosa were reported as 4.90 g/kg and 173.20 mg/kg respectively (Reanmongkol 
et al., 2007). In addition, Sabetghadam et al. (2013b) found that the oral lethal dosage, 
LD50, of pure MTG was 1098 mg/kg. MTG has been reported to cause less respiratory 
depression in animal models as compared to other narcotics (Jansen and Prast, 1988). 
3 
 
Sabetghadam et al. (2013a) discovered significant reduction of relative body weight and 
food intake in female rats when treated with 100mg/kg dose of MTG. Alterations in 
biochemical and hematological parameters, together with histopathological changes 
were observed especially in the high dose (100 mg/kg) treatment group. 
Acute oral administration of standardized methanolic extract of M. speciosa did 
not affect spontaneous motor activity, or food and water consumption in rats. The 
methanolic extract, however, led to a significant increase in alanine transaminase (ALT) 
and argininosuccinate lyase (ASL) (Harizal et al., 2010; Kapp et al., 2011). 
Nephrotoxicity was seen only at a 1000 mg/kg dose as evidenced by elevated creatinine 
levels. A histological examination showed the congestion of sinusoids, hepatocyte 
haemorrhage, fatty change, centrilobular necrosis and increased number of Kuppfer cells 
in the liver.  However, an acute treatment with the methanolic extract (100, 500 and 
1000 mg/kg doses) did not induce damage in the axons and dendrites of hippocampal 
neurons (Harizal et al., 2010).  
  Chronic M. speciosa users suffered anorexia, weight loss, hyperpigmentation, 
psychosis, constipation, insomnia, fatigue, poor concentration and hypothyroidism 
probably due to its suppression effect on thyroid-stimulating hormones (Suwanlert, 1975; 
Vicknasingam et al., 2010). Besides, M. speciosa users have been reported to experience 
nausea, vomiting, and diarrhoea with occasional reports of nystagmus and tremor 
(Grewal, 1932). Roche et al. (2008) reported the case of a 32-year-old male who was 
found having seizure-like movements and mouth-foaming. These movements persisted 
despite the person being given benzodiazepine treatment and intubation.   
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       Seizures and coma have been reported in humans when ketum extract was 
consumed and used whether it being for pain management, in combating opioid 
withdrawal symptons or as a recreational drug (Chan et al., 2007; Nelson et al., 2010; 
Vicknasingam et al., 2010). MTG is extensively metabolized in rat and human liver via 
phase I (hydrolysis and dealkylation) and II (conjugation to glucuronides and sulphates) 
reactions (Philipp et al., 2009). The MTG elimination half-life in rats was found to be 
approximately 4–9 h after a single dose (Janchawee et al., 2007). Parthasarathy et al. 
(2010) found that MTG has a mean half-life of 2.9±2.1 h after intravenous 
administration. Furthermore, Parthasarathy et al. (2010) has shown MTG has poor 
calculated absolute oral bioavailability of merely 3.03 % probably due to its poor 
aqueous solubility. Seizures were observed at very low doses (10 mg/kg) whilst 
convulsions were evident at a very high dosage (920 mg/kg) (Reanmongkol et al., 2007).  
          MTG demonstrated cytotoxic effects in vitro in human neuronal cells but toxicity 
could be lessened by using naloxone, an opioid antagonist. However, no genotoxicity 
was found in the mouse lymphoma gene mutation assay (Saidin et al., 2008; Saidin, 
2008). There was also no mutagenic activity using the Ames test in the presence and 
absence of metabolic activator S9 systems (Ghazali et al., 2011). The aqueous M. 
speciosa extract shows strong antimutagenic properties.  
            In summary, the various case studies on animals and humans suggest potentially 
toxic and lethal effects of M. speciosa preparations. The reasons are either due to long 
term consumption and accumulating effects or an acute overdose (Hassan et al., 2013). 
Therefore, the need for new analogues which possess good pharmacological activity and 
less toxicity has arisen and this is one of the rationales of the study in this thesis. 
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1.3 Other indole alkaloids of  mitragynine (MTG)  
The total alkaloid content in the M. speciosa leaves was in the range of 0.5% -
1.5% (Shellard, 1974). Mitragynaline, corynantheidaline, mitragynalinic acid and 
corynantheidalinic acid were discovered as new types of alkaloidsfrom Malaysian M. 
speciosa (Houghton et al., 1991). Other minor constituents found in mature leaves 
included mitragynaline, pinoresinol, mitralactonal, mitrasulgynine, 9-
methoxymitralactonine and mitralactonine and 3, 4, 5, 6-tetradehydromitragynine 
(Takayama et al., 1998). Nine corynanthe-type indole alkaloids namely MTG, 
speciogynine, speciociliatine, paynantheine, 7-hydroxymitragynine, mitragynaline, 
corynantheidaline, corynantheidine and isocorynoxeine were isolated from the leaves 
(Takayama et al., 2004) (Figure 1.2). 7-Hydroxyspeciociliatine was another indole 
alkaloid found in M. speciosa fruits (Kitajima et al., 2007). Two major metabolites: 
mitragynine pseudoindoxyl and 7-hydroxymitragynine, were obtained from microbial  
transformation (Zarembo et al., 1974) (Figure 1.2). 
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Figure 1.2  Mitragynine [(E)-methyl 2-(3-ethyl-8-methoxy-1,2,3,4,6,7,12,12b- 
       octahydroindolo[2,3-a]quinolizin-2-yl)-3-methoxyacrylate] related  
       indole alkaloid. 
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Major indole alkaloids  of young leaves of Thai M. speciosa are MTG (66%), 
paynantheine (9%), speciogynine (7%), 7-hydroxmitragynine (2%), and speciociliatine 
(1%) in which the relative composition varies greatly according to the geographical 
region and the season (Takayama et al., 2004) (Figure 1.2). Of the above mentioned 
alkaloids, MTG, paynantheidine, speciogynine, corynantheidine and 7-
hydroxmitragynine are known to be pharmacologically active (Takayama et al., 1998; 
Takayama et al., 2002; Matsumoto et al., 2004; Takayama et al., 2004). MTG possesses 
analgesic, antitussive, antidiarrheal, adrenergic and antimalarial activities whilst 
paynatheidine and speciogynine act as smooth muscle relaxants. With 66 % of the total 
alkaloid mixture, MTG is the main active alkaloid present in M. speciosa leaves that 
triggers opioid agonistic activity though it may not be the most potent psychoactive 
component when compared to other species (Grewal , 1932; Suwanlert, 1975;  Shellard, 
1989; Takayama et al., 2002; Takayama et al., 2004). 
 
1.4   Structure and opioid agonist activity of mitragynine-related indole derivatives 
 
Opioid agonistic activity is defined as the inhibition of the twitch contraction, 
which is reversed by the opioid antagonist naloxone. The opioid agonistic activities of 
the natural analogues of MTG and semisynthetic MTG derivatives were evaluated in 
guinea pig ileum contraction induced by electrical stimulation. MTG inhibited the twitch 
contraction, induced by electrical stimulation in a concentration-dependent manner, 
which was reversed by the addition of naloxone. However, the potency was one-fourth 
that of morphine.  
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  Takayama et al. (2002) found that corynantheidine (Figure 1.2) without a 
methoxy group at C-9 position (9-demethoxy analogues of MTG) lost agonistic activity 
in guinea pig ileum preparation when investigating the relationship between opioid 
agonist activity and the structure of indole alkaloids. This finding  has indicated that the 
methoxy group on C-9 in the MTG indole ring is essential for eliciting analgesic activity 
(Takayama et al., 2002). Corynantheidine did not show any opioid agonistic activity but 
had reversed the morphine-inhibited twitch contraction in guinea pig ileum. Takayama 
et al. (2002) later discovered that corynantheidine has a selective opioid antagonistic 
property on µ-opioid receptors based on receptor binding assays. Its antagonistic effect 
was in a concentration-dependent manner. These results suggest that corynantheidine 
inhibits the effect of morphine through functional antagonism of opioid receptors. 
Another analogue of MTG, 9-hydroxycorynantheidine (Figure 1.2), demonstrated 
inhibition on electrically induced twitch contraction in guinea pig ileum, but its 
percentage of maximum inhibition was less than that of MTG indicating lesser potency 
(Takayama et al., 2002).  Thus, it is suggested that 9-hydroxycorynantheidne is a partial 
agonist of opioid µ-receptors based on receptor binding assay. Put together, it is an 
interesting finding showing a shift in activity from full agonist via partial agonist to that 
of an antagonist on opioid receptors when there is a fine transformation of the functional 
group on C-9 from OCH3 (methoxy) to OH (hydroxy) or to H. Hence, it is found that the 
functional group on C-9 of mitragynine-related compounds determines the relative 
opioid agonistic activity (Takayama et al., 2002). On the other hand, the replacement of 
the methoxy functional group by the ethoxy and propoxy groups at C-9 on the indole 
ring  resulted in the reduction in both intrinsic opioid agonistic activity and the potency 
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as compared with those of MTG (Takayama et al., 2002). These results suggest that the 
methoxy group at the C-9 position determines its intrinsic compound activities on the 
opioid receptors and is the most suitable functional group for pharmacophore binding to 
opioid receptors (Takayama et al., 2002). In summary, although MTG derivatives 
possess basic skeleton which are completely different from that of morphine, they 
exhibit potent agonistic properties on opioid receptors in guinea pig ileum. The 
structural functions of methoxy group at position C-9 of the indole ring of the 
Corynanthe type indole alkaloid skeleton essentially contribute to the opioid agonistic 
activity (Takayama et al., 2002). By altering the functional group at the C-9 position, 
e.g., OCH3 > OH > H, of MTG, the activities of the compounds dramatically shifted 
from that of full agonists through partial agonists to that of antagonists on opioid 
receptors (Takayama et al., 2002). 
Speciociliatine (Figure 1.2), which is a minor constituent of M. speciosa, is the 
C-3 stereoisomer of MTG which takes a folded cis-quinolizidine conformation in the 
C/D-ring junction. The potency of this compound towards opioid receptors was 14-fold 
weaker than that of MTG in the guinea pig ileum test, indicating that the flat trans-
quinolizidine form of MTG was a more efficient conformation for exhibiting opioid 
agonist activity than the folded cis form of speciociliatine. Besides, the 4-quinolone 
derivative (Figure 1.2) retained almost the same opioid agonistic activity as that of MTG 
(Takayama et al., 2002) in the guinea pig ileum test.  
The oxidized derivatives of MTG (mitragynine pseudoindoxyl and 7-
hydroxymitrgynine) (Figure 1.2), exhibited a higher opioid agonist potency than MTG 
in the guinea pig ileum contraction test. The 7-hydroxymitragynine which showed full 
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agonistic intrinsic activity on opioid receptors was found to exhibit approximately 13 
and 46 times higher potency than those of morphine and MTG respectively. The 
introduction of a hydroxyl group at the C-7 position led to higher potency as compared 
with that of MTG. 7-hydroxymitragynine tended to show higher selectivity and affinity 
for µ receptors than that of MTG. However, the introduction of a methoxy or an ethoxy 
group at the C-7 position led to a dramatic reduction in both intrinsic activity and 
potency for opioid receptors.  It is concluded that the presence of the hydroxyl 
functional group at the C-7 position in MTG is essential for its improved potency 
towards opioid receptors. 
 
1.5 ß-carbolines derivatives 
           The de novo synthesis of MTG suffered the setback of having too many reaction 
steps (more than 22) and low yields (3-13 %) (Takayama et al., 1995; Ma et al., 2007; 
Ma et al., 2009;  Isabel, 2012). In addition, it requires a laborious purification process in 
order to obtain pure MTG. Therefore, total synthesis of mitragynine for further structure 
modification to obtain new analogues is not the objective of this thesis. 6-Methoxy-
tetrahydro-β-carboline derivatives (Figure 1.3a) were chosen as targeted synthesized 
compounds since they resemble intermediate products in the total synthesis of MTG,  
trans-tetrahydro-β-carboline, as shown in Figure 1.3b (Takayama et al., 1995; Ma et al., 
2007; Ma et al., 2009, Isabel, 2012). Furthermore, it is interesting to explore whether 
tetrahydro-β-carboline compounds possess similar analgesic or other useful biological 
activities as for mitragynine-related compounds. The Pictet-Spengler reaction mediated 
cyclization which served as an important key step in the total synthesis of MTG, is used 
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with modification, for the synthesis of 6-methoxy-tetrahydro-β-carboline in this study. 
The synthesis in this thesis for 6-methoxy-tetrahydro-β-carboline derivatives envisions 
much simpler reaction schemes with just a one pot reaction step. Therefore, the product 
yields are expected to be higher compared to that of the reaction involving many steps 
(Takayama et al., 1995; Ma et al., 2007; Ma et al., 2009, Isabel, 2012).  
            Tetrahydro-ß-carbolines (tetrahydro-pyrido(3,4-b)indole) and ß-carbolines 
(pyrido(3,4-b)indole) are naturally-occurring indole alkaloids with a β-carboline nucleus 
(Figure 1.3a and Figure 1.3b). They exhibit a broad range of potent pharmacological and 
biological activities (Patel et al., 2012). The reported pharmacological effects of this 
class of compounds comprise of antitumor, antiparasitic, antineoplastic (tubulin binding), 
anticonvulsive, hypnotic and anxiolytic, antiviral, antimicrobial as well 
as topoisomerase-II inhibition, cGMP-dependent processes inhibition and 
antiplasmodial activity (Hamsa et al., 2011,; Frost et al., 2011; Patel et. al., 2011). They 
may have other endocrinological functions especially 6-methoxytetrahydro-β-carboline 
derivatives (e.g. pinoline, an example of endogeneous β-carboline), which will be  
synthesized and studied in this thesis. 
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Figure 1.3a Structures and common name of some β-carbolines. 
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On the other hand, tetrahydro-ß-carbolines (tetrahydro-pyrido (3, 4-b)-indole) 
such as harmine and harmaline are central nervous system stimulants and act as 
selective but reversible inhibitors of MAO-A (RIMAs) (Santos et al., 2011; Santos et al., 
2012) that are similar to tyramine-containing foods, as compared to synthetic MAOIs 
such as phenelzine (Pardo et al., 2012). RIMAs help to replenish the body's supply of 
monoamines by slowing the breakdown of neurotransmitter and are used 
as antidepressants. Some examples are moclobemide, tranylcypromine, selegiline and 
phenelzine. The monoamines include neurotransmitters (serotonin, dopamine) and 
hormones (melatonin) (Santos et al., 2011; Santos et al., 2012). Harmine and harmaline 
can be safely consumed together with foods containing tyramine such as wine and aged 
cheese since they are RIMAs and they do not bind permanently to MAO (Pardo et al., 
2012). Therefore, tyramine would be competing with harmaline for binding site on the 
MAO-A enzyme.  Harmala alkaloids (alkaloids from Perganum harmala including 
harmine and harmaline) have been used to treat Parkinson's disease and essential tremor 
since they are benzodiazepine inverse agonist (Sourkes, 1999).    
             The BZRs (benzodiazepine receptors) in mammalian CNS (central nervous 
system) are known to mediate anxiolytic, anticonvulsant and sedative action. ß-carboline 
alkaloids are non-benzodiazepine antagonists that have been discovered to bind with 
high affinity to the BZRs and shown to antagonize the principle pharmacological actions 
of benzodiazepine. For example, 3-(ethoxycarbonyl)-ß-carboline and 3-
(methoxycarbonyl)-ß-carboline are benzodiazephine  antagonists that block the BZRs 
and exhibit opposite effects as to those of benzodiazepines in various animal behaviour 
models (Cao et al., 2007). Although pinoline (an endogeneous β-carboline) does not 
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have any affinity for the BZRs, significant anxiogenic, anticonvulsive and 
antidepressant properties of pinoline have also been found in some animal models at 
pharmacological dosage. These findings have suggested that the neuropharmacological 
effects of pinoline involve non-BZRs interaction mechanisms (Mcisaac, 1961; Mcissaac 
et al., 1961; Squires et al., 2004). 
            ß-carbolines molecules cause various side effects on the CNS including 
hallucinations, tremors, anxiety, anxiolytic, convulsions, anticonvulsant and sedation 
(Riba et al., 2001). Oral or intravenous harmine doses ranging from 30–300 mg have 
been reported to cause agitation, tachycardia, blurred vision and hallucinations. These  
pharmacological effects are partially due to the interaction of the  ß-carboline molecules 
with various receptor systems in the mammalian CNS, such as 5-HT receptors and 
BZRs (Giorgio et al.,2004; Cao et al., 2007). Both harmine and harmaline have been 
proven to act as acetyl cholinesterase inhibitors that stimulate striatal dopamine 
secretion in rats at high dose, thereby causing hallucinogenic effects in humans (Patel et 
al., 2012, Geyer and Franz, 2012). However, a lower dose (25-50 mg) indicates CNS 
stimulation, increases mental activity and produces a pleasant dreamy state for several 
hours. Whereas a higher doses (200-750 mg) cause the hallucinogenic effects. Harmine 
also causes some hallucinogenic effects at a dose of 150-200 mg via intravenous 
administration in humans (Riba et al., 2001; Cao et al., 2007; Santos et al., 2011; Santos 
et al., 2012 ). However, harmaline has been found to be hallucinogenic at doses greater 
than 1mg/kg after intravenous administration. In fact, harmaline is also orally active at a 
dose of 4mg/kg. Tetrahydroharmine has been reported to induce hallucinogenic effects 
at 300mg (Cao et al., 2007).  
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           In addition to this, 6-methoxyharmalan produces hallucinogenic effects and 
induces modest psychoactive action at oral doses of 1.5mg/kg (Cao et al., 2007; Geyer 
and Franz, 2012).  The harmala alkaloids are psychoactive in humans at oral doses of 
25-750 mg. Noticeable classic hallucinogens are thought to produce psychoactive 
effects via interaction with 5-HT2 serotonin receptors in the brain (Cao et al., 2007). 
However, so far, it has been inconclusive as to whether the ß-carboline alkaloids elicite 
hallucinogenic actions in a similar way to classical hallucinogen. It seems that the 6-
methoxyl moiety contributes to hallucinogenic effects of the compounds and higher 
conjugation in the tricyclic rings produces higher hallucinogenic effects (Geyer and 
Franz, 2012).  
  Interestingly, ß-carboline alkaloids have been demonstrated to play a crucial 
role in the processes of substance abuse and dependence (Cao et al., 2007). Cappendijk 
et al. (1993b) has reported that norharman produces prominent inhibitory effects on the 
naloxone-precipitated withdrawal syndrome in morphine dependent rats. Besides, high 
plasma levels of harman and norharman have been found in chronic alcoholics and 
heroin dependent humans. Chronic infusion of harman increases voluntary ethanol 
intake in rats and rapid discontinuation of these MAO inhibitors can cause a serious 
withdrawal syndrome.  Aricioglu-Kartal et al. (2003) has reported that harman and 
harmine have some beneficial effects on naloxone-precipitated withdrawal syndrome in 
rats, and harmine is more effective than harman in reducing the signs of morphine 
withdrawal syndrome. The use of β-carbolines has an advantage over the conventional 
treatment approach based on the alleviation of drug withdrawal symptoms (Howard et 
al., 1997). This group of compounds provides an alternative and effective approach to 
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interrupting and attenuating the consumption and craving for drugs such as heroin, 
fentanyl, methadone, codeine, opium, nicotine, amphetamine, caffeine and their 
combinations which upon ingestion or administration, leads to addiction. These have 
been shown to be intractable to treatment by other reagents (Howard et al., 1997). 
               Currently, researches have confirmed the effects of numerous ß-carboline and 
tetrahydro-ß-carbolines alkaloids of norharman, harman, harmine, harmaline, harmalan 
on the CNS and their affinity with BZRs and 5-HT receptors (Cappendijk et al., 1993a; 
Cappendijk et al., 1993b; Yin et al., 2010).  They are able to bind to GABA and I2 
(Imidazoline) receptors. These compounds might function as mild neuromodulators via 
inhibition effects on MAO, monoamine uptake and benzodiazepine receptor binding. 
Simultaneously, they have been increasingly studied in relation to alcoholism, where 
they might play a role in alcohol addiction either in etiological or in pathological states 
(Cappendijk et al., 1993a; Yin et al., 2010). Harmaline causes no known physical or 
psychological dependence. Howard et al. (1997) describes a method for treating various 
chemical dependencies via the administration of harmaline and other ß-carbolines. 
Surprisingly, it has been discovered that the β-carboline alkaloids are effective in the 
treatment of chemical dependency disorders, abuse syndromes or their combination in 
mammals (Howard et al., 1997).  
             Collins and his co-workers (1985 and 2009) have reported that N-methylated 
tetrahydro-ß-carbolines and ß-carbolines can be bioactivated to give endogenous 
neurotoxins. 1-Methyl-1,2,3,4-tetrahydro-ß-carboline-3-carboxylic acid is a precursor of 
mutagenic N-nitroso compounds and shows cytogenetic effects, and can cause neuronal 
cell death. Some ß-carbolines might act as co-mutagenic substances, precursors of N-
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nitroso compounds, and toxic compounds (Jing et al., 2014). Harmaline has both 
protective and toxic effects on neurons (Lee et al., 2000). A single injection of 
harmaline at 40 mg/kg in rats has very visible neurotoxic effects. The prototypic β-
carboline, 1-methyl-1,2,3,4-tetrahydro-β-carboline-3-carboxylic acid detected in some 
food items, is the possible causative substance of  the eosinophilia-myalgic syndrome 
(Pari et al., 2000). Some of the β-carbolines have been shown to be phototoxic to 
bacteria and insects and this might correlate with their ability to produce reactive 
oxygen species upon irradiation (Richard et al., 2008). ß-carbolines are DNA 
intercalating agents and DNA enzymes inhibitors which exhibit toxic and mutagenic 
effects either in prokaryotic or eukaryotic cells (Pari et al., 2000). 
 
1.6 Synthesis 
     1.6.1  Reduction of indole to indoline 
Lloyd and Gordon (2009) developed an efficient method of chemically reducing 
indole to indoline by using zinc dust and 85% phosphoric acid without polymerization. 
It has been reported that an efficient, palladium-catalyzed reduction of N-(tert-
butoxycarbonyl) indoles gives N-(tert-butoxycarbonyl) indolines in good yields, in the 
presence of polymethylhydrosiloxane (PMHS) as a reducing agent at room temperature 
(Chandrasekhar et al., 2006). A Brønsted acid catalyzed the process of transfer 
hydrogenation of indole derivatives with Hantzsch dihydropyridine as the hydrogen 
source enables an efficient synthesis of various optically active indolines with high 
enantioselectivities (Rueping and Antonchik, 2010). Sodium borohydride (NaBH4) in 
neat carboxylic acids sequentially reduces the indole double bond and alkylates nitrogen 
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atoms to produce N-alkylindolines (Gribble, 1998). An environmentally benign 
procedure for the hydrogenation of unprotected indoles is described by Aditya et al. 
(2011). The hydrogenation reaction is catalyzed by platinum on activated carbon and 
accelerated by p-toluenesulfonic acid in water as a solvent. The efficacy of the method is 
illustrated by the hydrogenation of a variety of substituted indoles to their corresponding 
indolines which were obtained in excellent yields (Scheme 1.1). 
N
H
R
R'
N
H
R
R'Pt/C, H2, HA, H2O
rt, 10-50 bar, 3h
Scheme 1.1 Reduction of indole to indoline using platinum on activated charcoal as  
        catalyst. 
 
  Borane-tetrahydrofuran (THF) in trifluoroacetic acid produces acid-stable 
H[OC(O)CF3]2.THF and constitutes a convenient, rapid, high yield method for the 
selective reduction of indoles to indoline in the presence of other functional groups 
(Bruce and David, 1978). Sodium cyanoborohydride in acetic acid or sodium 
borohydride in trifluoroacetic acid only reduces the double bond of indole to give 
indoline (Yatendra and Lennart, 1983). Tetrakis (dimethylamino) ethylene (TDAE), has 
been exploited for the first time as a mild reagent for the reduction of arenediazonium 
salts to aryl radical intermediates through a single electron transfer (SET) pathway. 
Cyclization of the aryl radicals produced in this way has led, in appropriate substrates, to 
the synthesis of indolines and indoles. There is also a report regarding cascade radical 
cyclizations of aryl radicals that are derived from arenediazonium salts. The relative 
ease of removal of the oxidized by-products of TDAE from the reaction mixture makes 
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the methodology synthetically attractive (Mohan et al., 2009). A method of reducing 
indole compounds to the corresponding indoline compounds substantially to be free of 
undesirable side reactions involves contacting an indole compound with a borane 
complex reagent, dioxyborane, in the presence of trifluoroacetic acid. This method is 
instantaneously and readily carried out and provides an excellent method for preparing 
certain indoline compounds from the corresponding indole compounds.  
 
1.6.2 Total synthesis of  tetrahydro-β-carbolines via Pictet-Spengler reaction 
Modification of the Pictet-Spengler reaction since its invention in 1911 has 
provided better enantiomeric purity, diastereo-selectivity, simplicity, shorter reaction 
time and higher yields. The modification process also includes the use of  different types 
of catalysts, reactants, reaction mediums and conditions (Pedro et al., 1990; Mark and 
Eric, 2004; Tschantz, 2012; Paresh et al., 2013). Bing and Anthony (2002) have 
designed a modified microwave method using solid wang resin with 1 % TFA  in 
toluene as a catalyst to shorten the reaction time at room temperature significantly from 
days to minutes with a high yield (> 80 %). Furthermore, tetrahydro-ß-carboline exhibits 
a broad spectrum of potent biological activities (4). Therefore, a simple and mild Pictet-
Spengler procedure has been designed to produce the 6-methoxy-tetrahydro-ß-carboline 
which contains no carbonyl group. 
The Pictet–Spengler reaction, as depicted in  Figure 1.4, is a special case of 
Mannich reaction in which a β-aryl ethylamine, such as tryptamine, undergoes 
condensation and ring closure with either an aldehyde or ketone (Rodolfo et al., 2013; 
Agarwal et al., 2013) using acidic catalyst at room or higher temperature (Pirc et al., 
21 
 
2011; Devesh et al., 2013). Amé Pictet and Theodor Spengler had, in 1911, reported the 
discovery of this reaction when they isolated 1-methyl-1, 2, 3, 4-tetrahydroisoquinoline 
from the cyclo condensation of β-phenethylamine with formaldehyde dimethyl acetal in 
the presence of hydrochloric acid. The reaction was later modified to accept other β-
phenethylamines such as N-alkyl, N-acyl and N-sulfonyl derivatives, proceeding via 
iminium, N-alkyliminium, N-acyliminium or N-sulfonyliminium ion formation, 
respectively (Larghi et al., 2005; Benjamin et al., 2006). 
 
N
H
NH
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H
NH2 RCHO
H+
H3CO
H3CO
 
 
                  Figure 1.4 Pictet-Spengler Reaction. 
 
Nucleophilic indole or pyrrole  rings give products with good yields under mild 
conditions, whereas less nucleophilic phenylic aromatic rings give poor yields despite 
the use of higher temperature and stronger acid presence. The original Pictet–Spengler 
reaction refers to the reaction of β-phenethylamine with 
dimethyl acetal of formaldehyde using hydrochloric acid as the catalyst to produce 
tetrahydro isoquinoline (Larghi et al., 2005; Benjamin et al., 2006). Pictet-Spengler 
reaction tends to show similar trends in reaction rate as the Mannich reaction where the 
aldehydes give better yields than the ketones. Currently, this reaction has been 
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successfully applied in solid-phase combinatorial chemistry (Nielsen et al., 2003; 
Nielsen et al., 2005). 
1.6.2.1   Mechanism of Pictet-Spengler reaction 
The Pictet-Spengler condensation reaction mechanism to form tetrahydro-β-
carboline is characterised by its initial formation of an iminium intermediate ion (4) 
after the acid catalyses the reaction of a tryptamine derivative and an aldehyde (Figure 
1.5) (Larghi et al., 2005). This is followed by 6-endo intramolecular cyclization of the 
imine and electrophilic substitution at the indole double bond (4). After de-protonation 
(5), the desired product (6) is formed (Larghi et al., 2005). It is the electrophilic imine 
double bond that drive through the cyclization. The reaction mechanism shown in 
Figure 1.5 is an example of a 6-endo-trig reaction, which is favoured by Baldwin's ring 
closure rules.   
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             Figure 1.5 Mechanism of Pictet-Spengler reaction. 
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1.6.2.2 Water as an effective medium of Pictet-Spengler reactions 
The Pictet–Spengler reaction strategy in water medium for C–C bond 
forming would contribute greatly to the development of an environmentally friendly 
process since it is cheap, readily available, and nontoxic compared to organic solvents. 
A recent review on C–C bond formation showed a significant improvement of the 
reaction rate in aqueous conditions which has been attributed to solvent polarity, 
hydration and hydrogen bonding. Condensation reaction of an amine and an aldehyde to 
give tetrahydro-β-carbolines in water with an acid catalyst is a mild, convenient and 
simple procedure and indicates the new variants of modified Pictet-Spengler reactions. 
Saha et al. (2007) discovered that in 10% TFA–water, aryl aldehydes have either 
electron-withdrawing or donating groups that undergo the Pictet–Spengler reaction with 
L-tryptophan or tryptamine to furnish endo cyclized products in good yields in 
comparison to 10% TFA–dichloromethane or p-TsOH–toluene. 
Unlike the traditional Pictet–Spengler protocol which involves aprotic solvents 
wherein aldehydes bearing electron-donating substituents have failed to undergo 
cyclization and furnished imines as the only product. This has been attributed to the 
decrease in the reactivity of the iminium ion intermediate in the aprotic solvent which in 
turn prevented the formation of tetrahydro-β-carbolines. Thus,  water, probably due to 
its unique abilities such as hydrogen bonding and high dielectric constant, appears to be 
a more efficient medium than toluene or dichloromethane in promoting the Pictet-
Spengler reaction (Saha et al., 2007). The driving force for endo cyclization, contributed 
by the electrophilicity of the aldiminium ions derived from aryl aldehydes, appears to be 
enhanced in water.  Furthermore, the Pictet–Spengler reaction in water exhibited better 
